Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bayer Completes Phase I of China TCM/OTC Production Plant

publication date: Jan 14, 2016
Bayer AG completed construction of the first phase of a $213 million China consumer healthcare manufacturing facility in Yunan province. The plant will make TCM and OTC products. In 2014, Bayer paid $578 million to acquire Dihon Pharma, a TCM/OTC company that had already begun building the facility. Bayer will use the plant to expand capacity for Dihon's products initially and its own later. The plant will be Bayer's second largest production facility for consumer healthcare in Asia and will become a center for Bayer's global OTC business. More details....

Stock Symbol: (XETRA: BAYN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital